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Abstract
A large investment is required to develop, license and deploy a new antimalarial drug. Too often,
that investment has been rapidly devalued by the selection of parasite populations resistant to the
drug action. To understand the mechanisms of selection, detailed information on the patterns of
drug use in a variety of environments, and the geographic and temporal patterns of resistance is
needed. Currently, there is no publically-accessible central database that contains information on
the levels of resistance to antimalaria drugs.
This paper outlines the resources that are available and the steps that might be taken to create a
dynamic, open access database that would include current and historical data on clinical efficacy, in
vitro responses and molecular markers related to drug resistance in Plasmodium falciparum and
Plasmodium vivax. The goal is to include historical and current data on resistance to commonly used
drugs, like chloroquine and sulfadoxine-pyrimethamine, and on the many combinations that are
now being tested in different settings. The database will be accessible to all on the Web.
The information in such a database will inform optimal utilization of current drugs and sustain the
longest possible therapeutic life of newly introduced drugs and combinations. The database will
protect the valuable investment represented by the development and deployment of novel
therapies for malaria.
The problem
Whenever drug treatment is required to control a patho-
gen, selection of drug resistance is inevitable [1]. The huge
size of pathogen populations and their short generation
times guarantee the outcome. Plasmodium falciparum is a
prime example. In humans, an acute infection can pro-
duce a population as high as 1011 haploid parasites, so
that mutations have ample scope to occur [2]. In the obli-
gate sexual cycle, reassortment and recombination can
"reshuffle the deck" for rapid evolution of new resistant
genotypes in each generation. Thus, favoured combina-
tions of genes can arise fairly quickly, even if more than
one mutant gene is required for resistance. These sets of
genes can, of course, also be separated during the sexual
cycle but under the strong selection that drugs can exert,
even a multigenic, resistant genotype may become fixed in
a population.
The impact of this strong selection has been revealed at
many different levels. Most important, as the use of chlo-
roquine increased, drug resistance evolved in parasite
populations and childhood mortality from malaria
increased, even as all-cause mortality in children
decreased [3-5]. The sequence of the P. falciparum genome
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has recently been published [6] and this has made it pos-
sible to trace the ancestry of highly drug-resistant para-
sites. These studies show that parasites resistant to
chloroquine and sulfadoxine-pyrimethamine have arisen
relatively rarely, but they have spread widely from a few
initial foci in "selective sweeps" of the parasite population
[7-11]. This new view affects many of the assumptions
that underlie models of the speed at which resistance
evolves [12] and inform practical decisions about changes
in drug policy. Parasites without borders make it abso-
lutely essential that the emergence of drug resistant popu-
lations be "tracked" worldwide; a resistant parasite that
arises in Southeast Asia may travel rapidly to East Africa.
This improved understanding of the evolution of drug
resistance has come from a relatively simple situation.
Until recently, the number of antimalaria drugs in com-
mon use was small: chloroquine and sulfadoxine-
pyrimethamine in Africa and the Americas, with meflo-
quine and more recently, mefloquine-artesunate in
Southeast Asia[13]. As chloroquine and sulfadoxine-
pyrimethamine have lost their efficacy, combination
drugs have been strongly endorsed as the most effective
next step [14]. In response to this emphasis, many differ-
ent combination drugs, most containing an artemisinin
derivative are being used in various countries, especially
in East Africa (Figure 1. Many of these combinations have
shown excellent initial efficacy in drug trials [13], but only
mefloquine/artesunate has a long enough history to allow
a strong prediction of the useful therapeutic life of these
combinations [15]. It is particularly important to estab-
lish a baseline for effectiveness of new drugs and combi-
nations so that any subsequent changes can be seen. This
complex situation underlines the importance of regional
surveillance of drug use, efficacy and effectiveness as these
new combinations are tried in a variety of demographic
and ecological settings. What has worked well for a long
time in Thailand may not be so long lived in Tanzania
[16]!
Appropriately, the gold standard for drug efficacy has
been the outcome of clinical treatment. When patients are
treated with the drug, do they recover? The substantial
expense and logistical difficulty to change the recom-
mended drug treatment have led most countries to rely on
a large increase in clinical treatment failure before initiat-
ing a change [17]. Systematic studies have shown repeat-
edly that assessment in vitro of drug efficacy in local
parasite isolates can give an early warning of rising drug
resistance in vivo [18-20]. In addition, when molecular
correlates of drug resistance are known, the prevalence of
resistant alleles can also give early warning of evolving
resistance in the parasite population [21-23]. In all three
approaches, the temporal and geographic patterns of
resistance are most informative. When the in vitro toler-
ance of parasites to a drug is rising or when the prevalence
or the geographic range of resistant alleles is increasing,
clinical drug failure is likely to increase as well. Figure 2
shows a small example of the linkage among the three
parameters. In this data set, the increase in the in vitro IC50
values and the increased prevalence of the triple mutant
allele of P. falciparum dhfr preceded by several years the
increase in sulfadoxine-pyrimethamine treatment failure
among young children in Coastal Kenya. Similar studies
will be needed to determine whether the lags between
these parameters observed in Kilifi will be similar in other
sites or for other drugs, but it is clear that the in vitro
Surveillance of efficacy of sulfadoxine-pyrimethamine in Kilifi,  Kenya 1988–2002 Figure 2
Surveillance of efficacy of sulfadoxine-pyrimethamine 
in Kilifi, Kenya 1988–2002. Pyrimethamine efficacy in 
vitro, prevalence of 51I/59R/108N alleles of P. falciparum dhfr 
and clinical efficacy of sulfadoxine-pyrimethamine in treat-
ment of uncomplicated malaria in children were separately 
assayed in over the indicated period using standard assays 
[52, 69, 70]. The data are used with permission of Dr. Alexis 
Nzila and Dr. Edward Mberu Kamau.
Drug combinations in use or in trials Figure 1
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increase in IC50 values and the increase in the molecular
marker can provide an early warning of the onset of clini-
cal treatment failure. The community will need similar
data sets in many different settings for all of the drugs in
use to manage effectively the current drugs and any novel
drugs that are introduced in the future.
A solution: a real-time public database
A large amount of data of all three kinds – in vivo patient
response to treatment, in vitro response of patient isolates
to drugs and prevalence of molecular markers of drug
resistance – is currently being collected in malaria-
endemic areas. Unfortunately, much of this information
is sitting unused and unusable in journals, meeting
abstracts, Ministry of Health reports and other informal
sites. An open, public database would record the data in
real time so that the data could be accessed, analysed and
productively used by all interested parties.
What resources are currently available?
There are already many sources of historical data that
could be incorporated readily into such a database. First,
WHO has just published a report on the "Susceptibility of
Plasmodium falciparum to antimalarial drugs. A report on
global monitoring 1996–2004". This report gathers the
available published and unpublished information on the
tools used in monitoring drug efficacy, the data from
endemic countries and the trends observed in the moni-
toring period [13]. The report, underpinned by a web-
based global database, serves as a meta-analysis of the cur-
rent situation, but it does not provide access to the origi-
nal data. This WHO database serves primarily the purpose
of documenting the evidence for treatment policy change
in malaria endemic countries. It is updated every three
months and includes analysis of trends in the data. The
nature and the country ownership of these data available
to WHO do not lend themselves to direct deposition in a
universal database. However, sharing of these data for
specific and agreed purposes is possible. In this way, the
information in the WHO database could form the core of
an open database.
A second valuable source is the national surveillance pro-
grammes that have comprehensive data sets. For example,
the IMPACT-Tz programme, (Interdisciplinary Monitor-
ing Project for Antimalarial Combination Therapy in Tan-
zania, [24] is a joint programme of the United States
Centers for Disease Control and the Ifakara Health
Research and Development Centre and includes partners
at the National Institute for Medical Research and
Muhimbili University College of Health Sciences, Dar-es-
Salaam, Tanzania, London School of Hygiene and Tropi-
cal Medicine and the Swiss Tropical Institute. This study
focuses on the effectiveness of artemisinin-based combi-
nation therapy in areas with intense malaria transmission.
Similar programmes with many collaborators have been
launched in other countries and the inclusion of such
national data sets would be extremely valuable.
Third, several networks for regional monitoring of current
trends have been established. The prototype is EANMAT-
the East African Network for Monitoring Antimalarial
Treatment. This is a regional network that established
common protocols to monitor the efficacy of the first and
second line drugs in each national control programme
[25,26]. The data are collected annually and reported on a
common website [27]. Similar networks have been estab-
lished in other regions of Africa, Southeast Asia and South
America (Figures 3, 4). Collection of data from these net-
work web sites could be an important contribution to a
comprehensive international database. Figure 4 shows a
map of some regional networks that have been organized
so far.
Fourth, there are supra-national networks that are collect-
ing and archiving data on parasite response to drugs and
on polymorphisms related to resistance. For example, the
Pasteur Institutes in Senegal, French Guyana, Madagascar,
Cambodia and Ivory Coast are combining field studies,
molecular biology and in vitro monitoring of drug
responses in parasite populations to identify early signs of
declining drug efficacy [28]. The US Department of
Defense also has a comprehensive network collecting data
on various emerging infectious diseases Global Emerging
Infections System: [29], and malaria is included in their
portfolio. The WHO and the Multilateral Initiative Against
Malaria have also formed a network in five African coun-
tries [30]. The varied environments represented by these
centres, their common protocols and their integrated
approach are exactly the sort of input one would want to
include in a common database.
Fifth, there is a rich archive of data on the mechanisms of
action, interactions between drugs and the speed with
which resistance to antimalarial drugs can be selected in
rodent models [1,31-34]. Inclusion of these data in the
central archive can also provide information on the
genetic basis for resistance to particular drugs, informa-
tion that can then be compared with data gathered in
human parasites.
Finally, there is a growing archive of molecular data on the
prevalence of alleles implicated in resistance to chloro-
quine, sulfadoxine-pyrimethamine, mefloquine, quinine
and artemisinin related compounds [35]. Much of this
information is contained in publications and meeting
abstracts and its usefulness is often limited because the
reported data derive from a limited area or capture the
information from a single time point. Like the in vitro
assessments, the molecular data do not relate directly toMalaria Journal 2006, 5:48 http://www.malariajournal.com/content/5/1/48
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clinical outcomes in individual patients; too many impor-
tant host factors influence the clinical outcome. The utility
of the molecular markers lies in the overview of the geo-
graphic and temporal trends that can easily be discerned
from coordinated sets of the data [21-23,36,37]. For
example, alleles of P. falciparum Pfcrt that carry the key
K76T mutation are strongly associated with resistance to
chloroquine and the prevalence of that allele declined
dramatically in Malawi after chloroquine was replaced
with sulfadoxine-pyrimethamine as the first line drug in
1993 [38]. This decline was paralleled by a return of the
clinical efficacy of chloroquine in Malawi. Similar associ-
ations of molecular markers for sulfadoxine-pyrimeth-
amine and mefloquine have been defined [21,39,40], and
recent data have identified markers that may be useful in
tracking quinine and artemisinin resistance as well [40-
42]. More work will be needed to determine the clinical
significance of some of these newly identified molecular
changes. When these correlations have been made, similar
monitoring of baseline levels and any changes in allelic
prevalence could follow the evolution of resistance to
other drugs as they are introduced. The increase in partic-
ular alleles could serve as an early warning as resistant par-
asites gain ground in an area. As with the monitoring of in
vitro drug sensitivity, there is a lag between the rising prev-
alence of a resistant allele and the increase observed in
clinical failure and that lag period will need to be deter-
mined for each location.
The ease of the molecular studies, the fact that the analysis
requires only a few drops of blood and the stability of
dried samples on simple filter papers makes this an attrac-
tive approach. In fact, several of the regional networks are
routinely archiving these dried blood samples, so that
molecular studies will be easy to realize, even if the sam-
ples are not analysed immediately. For many of the new
drugs and combinations, molecular correlates are yet to
be defined. In these cases, archives of dried samples could
be used retrospectively (with appropriate patient consent)
to define baseline data on allelic prevalences from periods
before the drugs were even introduced. This would be an
extremely valuable dataset from which to gauge temporal
changes after deployment of new drugs and combinations
Many of the national and regional programmes are
Regional surveillance networks Figure 3
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archiving samples in this way, and numerous laboratories
in endemic countries have the facilities and expertise to
analyse the samples for the relevant genetic changes. As
data of this kind are published, collation of the molecular
markers will allow users to query the database to follow
geographic and temporal trends in real time [43].
How would a database work?
The format of such a database will require careful plan-
ning by the whole malaria community. The sources, such
as those cited above, could provide three complementary
types of data:patient responses to drugs, in vitro efficacy of
drugs in use, or those that might be adopted, and molec-
ular markers correlated with resistance to drugs. The clin-
ical data will be the most complex and varied, and it
seems sensible to create separate sections of the database
with easy linkages among the three parts. The three
approaches provide complementary information and
each of them will need to be integrated into the overall
database.
The first step is to decide what data are to be included and
how these are to accessed. Although this review focuses on
P. falciparum, there are also data on P. vivax clinical effi-
cacy and some data on molecular correlates of resistance,
as well. These should also be included [44,45]. A meeting
of potential contributors and end-users would be a sensi-
ble way to initiate the discussion. At the outset, published
information can be collected, and then added to the base
as new information becomes available, as is currently
done with genomic and protein structure data. As noted
above, there are significant data in smaller databases
already and, with permission, these could be incorporated
reasonably readily into the central core, with links to each
individual database. There are some models that may be
useful. For example, there is a very impressive HIV site
that includes a wide range of information, including drug
effectiveness, resistant mutants and the relationship to
patient outcomes after treatment [46].
The many "omics" databases that have been created in
recent years have given considerable experience in manag-
ing and integrating large volumes of data. At the outset, it
will be critical to reach a consensus on standardized input
and output. Such a database will be useful only if it is
maintained, so the input format must be accessible and
Some regional networks for surveillance of antimalarial drug efficacy Figure 4
Some regional networks for surveillance of antimalarial drug efficacy.Malaria Journal 2006, 5:48 http://www.malariajournal.com/content/5/1/48
Page 6 of 9
(page number not for citation purposes)
straightforward. Moreover, the output must be useful to a
wide variety of users, from individual scientists and health
care professionals to those charged with making public
health decisions. Simplicity of input, user friendly inter-
faces and broad utility of the output are not easy to attain,
and the creation of the database will require sophistica-
tion. However, this task can only begin when the commu-
nity has decided on input and output.
Most people envisage maps as one useful output. The
MARA project that integrated climate data with demo-
graphic information and malaria incidence showed
clearly the power of a visual presentation [47-49]. Simi-
larly, WHO/GMP has informative maps for many individ-
ual African countries [50]. The capacity to view resistance
on both continent wide and regional bases and to exam-
ine changes in these parameters over time would greatly
enhance our understanding of the evolution of resistance.
What are the anticipated problems?
Technical issues
Assembling the data will not be an easy task and clinical
data present the biggest challenge. Even the data in organ-
ized trials of drug efficacy are heterogeneous, and when
more information from routine surveillance is included,
the problem is compounded. Although WHO standard
protocols have been published since 1996, the inclusion
criteria, protocols used and end points measured in partic-
ular studies frequently diverge based on the needs and
constraints of each particular study. It has been recog-
nized for a long time that the approaches appropriate for
areas of very high transmission are not sensible for those
where malaria is rare [51,52]. The past controversy over
whether patients should be followed for only 14 days after
treatment to avoid categorizing new infections as recru-
descence, or for 28 days or more to observe late return of
the parasites is a good example. Even when one attempts
to use molecular markers to distinguish new infections
from those that have recrudesced, many difficulties still
remain [53].
These complexities are not unique to malaria; they occur
whenever clinical assessments need to be made. Meta-
analyses like those done in the Cochrane Systematic
Reviews [54] are now routinely used to compare protocols
and outcomes in a wide variety of clinical situations to
identify the best practice based on hard evidence. In fact,
several analyses of antimalaria drug efficacy have been
published in the Cochrane series in the last 2 years [55-
58]. A comprehensive database for the much more diffi-
cult and contentious problem of all clinical trials has also
been recently proposed [59]. A major issue for antimalar-
ial drug resistance is that most of the historical data on
drug efficacy were collected under the 1996 WHO recom-
mendation for 14 day follow-up, but many studies have
now shown that this short protocol markedly underesti-
mates true drug failure, especially for long-lived drugs
[60]. The WHO guidelines were revised in 2001 to recom-
mend at least 28 days of follow-up. This presents a
dilemma; exclusion of these earlier data would ignore a
huge amount of extremely valuable information. After all,
clinical treatment failure before 14 days is a very impor-
tant finding, even if apparent adequate clinical response
within that time often masks parasites that recrudesce
within 28 days [60]. Despite these complexities, retrospec-
tive analyses by White and his colleagues [60,61] have
been used productively to draw common conclusions
from the many clinical trials that have been conducted.
A consensus on the quality controls, endpoints, inclusion
criteria and sampling protocols used in each study is a pre-
requisite. Then, detailed information on each study can be
entered in the database with a controlled vocabulary.
Under this system, an individual user can decide whether
to include studies with a 14 day follow-up in the analysis
and query the database with that stipulation as one argu-
ment. As long as the 14-day studies can easily be identi-
fied in searches of the database, an individual can access
and analyse the data with that limitation in mind.
Assessment of drug sensitivity in vitro avoids many of the
host factors that complicate in vivo studies and this
approach makes it possible to determine the level of
resistance to individual drugs. With the widespread adop-
tion of combination therapies, this kind of assessment
will be even more important for following trends in resist-
ance to the components of the various combinations. It is
often impossible to conduct therapeutic efficacy tests for
each component, owing to ethical problems, non-availa-
bility of the drug as a single therapy and the need to study
a large number of patients. In vitro tests can be used to
monitor susceptibility to each drug in a combination. This
is especially important in the current situation where
many different partners are being paired with artemisinin
derivatives. Failure of the partner may be more likely than
resistance to the artemisinin component, but resistance to
the artemisinins would compromise virtually all of the
combinations currently in use or development. At the
moment, in vitro efficacy studies are the only tool availa-
ble to track this key parameter.
There are numerous difficulties in comparing the absolute
IC50 values derived in different laboratories. It is particu-
larly important to distinguish studies that assess contem-
porary patient isolates, rather than those limited to
culture-adapted reference strains. Fresh patient isolates
may contain more than one strain, but they are important
because they do reflect the current situation. In addition,
other parameters can differ from one laboratory to
another, including the media used, the protocols forMalaria Journal 2006, 5:48 http://www.malariajournal.com/content/5/1/48
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assessment of parasite growth and the reference strains
assessed [62,63]. Again, discussion of these differences
will be needed in order to define parameters that will
allow comparison of data collected in different laborato-
ries. For example, the most valuable information may be
the temporal trend in values measured with a consistent
protocol in a particular laboratory, especially if those val-
ues compare the response of freshly isolated parasites
with standard reference strains.
The inclusion of molecular data on alleles correlated with
resistance to a particular drug presents fewer complexities.
There are various protocols for the determination of alle-
les and the sensitivity of the protocols to minor alleles in
the isolates from patients with polyclonal infections varies
enormously [64-67]. Despite these differences, the overall
assessment of the prevalence of resistant alleles in a para-
site population is fairly consistent among the various
approaches.
Molecular analysis is also used to distinguish recrudes-
cence from new infections in patients in whom parasites
return later than 14 days after treatment. The alleles of
very polymorphic genes like msp1, msp2 and GLURP are
often used, and the sequence of the whole genome now
allows microsatellite or single nucleotide polymorphisms
to be used as markers. Both the sensitivity of the detection
used and the definition of a new or old parasite have a
profound influence on the assessment of success or of
drug failure [53], so a common definition of these issues
is needed if data from clinical different studies are to be
compared.
Human and programmatic issues
Many human factors will also need to be resolved if such
a database is to be created. Gathering data with all of these
methods is a complex, demanding activity that requires a
high level of professional training and dedication. Rapid
release of these data to a database before publication
would deprive the scientist of professional recognition for
the hard work involved in data collection. Again, this is
not unique to the malaria community; the genome and
public health surveillance networks have faced similar
problems. At the outset, this difficulty can be mitigated by
establishing the database with published data. Ultimately,
the community will need to devise ways of recognizing
and rewarding the important effort of surveillance. With-
out this recognition, the motivation to collect high quality
data may be low and inclusion of inaccurate data serves
no one.
The use of human samples raises important issues of con-
sent and patient privacy, even when only the parasite
parameters are evaluated. If molecular or in vitro analysis
or publication of patient data in a database is anticipated,
the appropriate informed consent can be sought from the
patient or guardian, at the time of the study. However, for
archival samples, this is usually impossible. These issues
will need to be carefully addressed for each data set that is
considered for inclusion in a database that is publicly
available. Again, many of these issues have been
addressed in other databases and the needed safeguards
can be built into the database. A recent paper from EM
Kamau addresses thoughtfully many of these issues [68].
Conclusion
The bottom line is clear: continuing to treat patients with
failed or failing antimalarial drugs is a major and unnec-
essary cause of mortality. The introduction of artemisinin-
based combinations may reverse that trend, but resistance
to these drugs will evolve eventually. WHO now recom-
mends that review and change of the antimalarial treat-
ment policy should be initiated when the cure rate with
the current recommended medicine falls below 90% (as
assessed in the course of surveillance monitoring) and the
new recommended treatment should have an average cure
rate of ≥95% as assessed in clinical trials. It is crucial to
establish and maintain close surveillance as new drugs are
introduced so that they will have the maximum useful
therapeutic life. The first step is to assemble and integrate
the information now available, and assemble a compre-
hensive real time database that is accessible to all. Post-
poning this synthesis will only make it harder to integrate
the current information. It is imperative to act now to
make the community decisions that will initiate this
effort.
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